CLINICAL_TRIALS ClinicalTrials.gov record update

PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05219500
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:03.319428+00:00
Published At: 2026-04-03T00:00:00+00:00
Record Updated At: 2026-04-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Castration Resistant Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-03"
protocolSection.identificationModule.nctId: "NCT05219500"
protocolSection.identificationModule.officialTitle: "PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I\u0026T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial."
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.